TY - JOUR
T1 - Mode of primary cancer detection as an indicator of screening practice for second primary cancer in cancer survivors
T2 - a nationwide survey in Korea
AU - Suh, Beomseok
AU - Shin, Dong W.
AU - Kim, So Y.
AU - Park, Jae Hyun
AU - Chang, Weon Y.
AU - Lim, Seung P.
AU - Yim, Chang Yeol
AU - Cho, Be Long
AU - Park, Eun Cheol
AU - Park, Jong Hyock
PY - 2012/11/26
Y1 - 2012/11/26
N2 - Background: While knowledge and risk perception have been associated with screening for second primary cancer (SPC), there are no clinically useful indicators to identify who is at risk of not being properly screened for SPC. We investigated whether the mode of primary cancer detection (i.e. screen-detected vs. non-screen-detected) is associated with subsequent completion of all appropriate SPC screening in cancer survivors.Methods: Data were collected from cancer patients treated at the National Cancer Center and nine regional cancer centers across Korea. A total of 512 cancer survivors older than 40, time since diagnosis more than 2 years, and whose first primary cancer was not advanced or metastasized were selected. Multivariate logistic regression was used to examine factors, including mode of primary cancer detection, associated with completion of all appropriate SPC screening according to national cancer screening guidelines.Results: Being screen-detected for their first primary cancer was found to be significantly associated with completion of all appropriate SPC screening (adjusted odds ratio, 2.13; 95% confidence interval, 1.36-3.33), after controlling for demographic and clinical variables. Screen-detected cancer survivors were significantly more likely to have higher household income, have other comorbidities, and be within 5 years since diagnosis.Conclusions: The mode of primary cancer detection, a readily available clinical information, can be used as an indicator for screening practice for SPC in cancer survivors. Education about the importance of SPC screening will be helpful particularly for cancer survivors whose primary cancer was not screen-detected.
AB - Background: While knowledge and risk perception have been associated with screening for second primary cancer (SPC), there are no clinically useful indicators to identify who is at risk of not being properly screened for SPC. We investigated whether the mode of primary cancer detection (i.e. screen-detected vs. non-screen-detected) is associated with subsequent completion of all appropriate SPC screening in cancer survivors.Methods: Data were collected from cancer patients treated at the National Cancer Center and nine regional cancer centers across Korea. A total of 512 cancer survivors older than 40, time since diagnosis more than 2 years, and whose first primary cancer was not advanced or metastasized were selected. Multivariate logistic regression was used to examine factors, including mode of primary cancer detection, associated with completion of all appropriate SPC screening according to national cancer screening guidelines.Results: Being screen-detected for their first primary cancer was found to be significantly associated with completion of all appropriate SPC screening (adjusted odds ratio, 2.13; 95% confidence interval, 1.36-3.33), after controlling for demographic and clinical variables. Screen-detected cancer survivors were significantly more likely to have higher household income, have other comorbidities, and be within 5 years since diagnosis.Conclusions: The mode of primary cancer detection, a readily available clinical information, can be used as an indicator for screening practice for SPC in cancer survivors. Education about the importance of SPC screening will be helpful particularly for cancer survivors whose primary cancer was not screen-detected.
UR - http://www.scopus.com/inward/record.url?scp=84869889595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869889595&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-12-557
DO - 10.1186/1471-2407-12-557
M3 - Article
C2 - 23181637
AN - SCOPUS:84869889595
VL - 12
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
M1 - 557
ER -